Aprutumab ixadotin

N/A

Report date: 2024/02/05 14:07:39

Base Information

Drug NameAprutumab ixadotin

Drug Alias NameBAY-1187982

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Non-cleavable linkerBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC)

Mechanisms of ActionTubulin polymerisation inhibitorsFibroblast growth factor receptor 2 antagonists

TargetsFibroblast growth factor receptor 2Tubulin

Therapy Area/IndicationsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited StatesSingaporeSouth Korea

CombinationsNo

Global Highest StatusDiscontinued (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesBayer AG

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesBayer AG

Active IndicationsN/A

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A